Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Trial Details

NCT ID

NCT05462496

Phase

PHASE2

Sponsor

Icahn School of Medicine at Mount Sinai

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Biopsy
• FOLFIRINOX
• Ciprofloxacin
• Metronidazole
• Pembrolizumab
• Surgical Resection

Locations (sample)

• New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

• Histologically confirmed pancreatic adenocarcinoma. Histologies other than adenocarcinoma, or any mixed histologies, will NOT be eligible. \*Note: …
• Clinical stage T1-3, N0-2, M0 (per AJCC 8th ed)
• Resectable pancreatic cancer as defined by NCCN Guidelines 2.2021 and based on pancreatic protocol dual-phase CT imaging. Multi-detector computed t…
• No arterial tumor contact (celiac axis \[CA\], superior mesenteric artery \[SMA\], or common hepatic artery \[CHA\])

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.